(A) Overall survival (OS).
Factors | Studies, n | OS for HCC (95%CI) | I2 | Model used |
---|---|---|---|---|
Detection method | ||||
ELISA | 6 | 2.311 (1.858—2.874) | 31.4% | Fixed effects |
Radioimmunoassay | 2 | 2.279 (1.448—3.587) | 55.6% | Fixed effects |
Study design | ||||
Clinical trail | 3 | 2.073 (1.615—2.660) | 0% | Fixed effects |
Cohort | 5 | 2.745 (1.993—3.781) | 31.8% | Fixed effects |
Study location | ||||
Asia | 5 | 2.489 (1.922—3.223) | 41.6% | Fixed effects |
North America | 2 | 2.082 (1.546—2.802) | 0% | Fixed effects |
Europe | 1 | 3.2 (2.4—10.5) |